https://www.selleckchem.com/products/gdc-0068.html
Our results provide valuable implications for the development of DTMUV vaccines and therapeutics. Borderline ovarian tumors (BOTs) although rare, have shown an increase in the incidence worldwide. Although the survival rate is high, the recurrence rate is estimated to be between 5% and 34%. The objective of this study was to identify risk factors for recurrence of BOTs. This retrospective multicenter study included 493 patients treated surgically for BOT between January 2001 and December 2018. Thirty-seven patients showed recurrence (g
Like
Comment
Share
